SCHEMBL281996

SCHEMBL281996

CCc1cc(N=C=O)ccc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
GABRA1 P14867 2/20 0.48
GABRB2 P47870 2/20 0.48
CYP3A4 P08684 3/20 0.46
TRPA1 O75762 1/20 0.46
TSHR P16473 1/20 0.42
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
CYP1A2 P05177 1/20 0.36
IDO1 P14902 1/20 0.35
KDM4E B2RXH2 3/20 0.34
HTR2A P28223 2/20 0.34
SLC6A4 P31645 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11552139 0.87 MAPK1 (0.66) MAPK1TDP1GABRA1GABRB2CYP3A4
SCHEMBL27318232 0.84 MAPK1 (0.61) MAPK1TDP1GABRA1GABRB2CYP3A4
SCHEMBL1122281 0.84 MAPK1 (0.61) MAPK1TDP1GABRA1GABRB2CYP3A4
SCHEMBL31182116 0.84 MAPK1 (0.61) MAPK1TDP1GABRA1GABRB2CYP3A4
SCHEMBL11857603 0.81 MAPK1 (0.46) MAPK1TDP1GABRA1GABRB2CYP3A4
SCHEMBL895208 0.81 CYP3A4 (0.48) MAPK1TDP1GABRA1GABRB2CYP3A4
SCHEMBL24999152 0.79 CYP3A4 (0.61) MAPK1TDP1GABRA1GABRB2CYP3A4
SCHEMBL109348 0.79 CYP3A4 (0.56) MAPK1TDP1GABRA1GABRB2CYP3A4
SCHEMBL7247754 0.78 MAPK1 (0.46) MAPK1TDP1GABRA1GABRB2CYP3A4
SCHEMBL29376406 0.78 MAPK1 (1.00) MAPK1TDP1CYP3A4TRPA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
EP-2428506-B1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) 2014-03-05 EP disclosed
EP-2428506-A1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF Jiangsu Provincial Institute Of Materia Medica Co. (CN) 2012-03-14 EP disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed
CN-101372475-B Aromatic heterocyclic substituted diphenyl urea derivative and application thereof NANJING UNIVERSITY OF TECHNOLOGY 2012-01-04 CN disclosed
CN-101671301-A Heterocyclic substituent acardite derivate and application thereof JIANGSU PROVINCIAL INST OF MAT 2010-03-17 CN disclosed
CN-101372475-A Aromatic heterocyclic substituted diphenyl urea derivative and application thereof NANJING UNIVERSITY OF TECHNOLOGY (CN) 2009-02-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 MAPK1 3213/4885TDP1 2286/4885GABRA1 3621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.